DE602005016405D1 - Verbesserung der bildqualität im auge - Google Patents

Verbesserung der bildqualität im auge

Info

Publication number
DE602005016405D1
DE602005016405D1 DE602005016405T DE602005016405T DE602005016405D1 DE 602005016405 D1 DE602005016405 D1 DE 602005016405D1 DE 602005016405 T DE602005016405 T DE 602005016405T DE 602005016405 T DE602005016405 T DE 602005016405T DE 602005016405 D1 DE602005016405 D1 DE 602005016405D1
Authority
DE
Germany
Prior art keywords
picture quality
improving picture
zeaxanthin
quality eye
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005016405T
Other languages
German (de)
English (en)
Inventor
John Barbur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of DE602005016405D1 publication Critical patent/DE602005016405D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Eye Examination Apparatus (AREA)
DE602005016405T 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge Expired - Lifetime DE602005016405D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015189 2004-06-29
PCT/EP2005/006168 WO2006002735A1 (en) 2004-06-29 2005-06-08 Improvement of image quality in the eye

Publications (1)

Publication Number Publication Date
DE602005016405D1 true DE602005016405D1 (de) 2009-10-15

Family

ID=35782481

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016405T Expired - Lifetime DE602005016405D1 (de) 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge

Country Status (9)

Country Link
US (2) US20080045605A1 (cg-RX-API-DMAC10.html)
EP (1) EP1761254B1 (cg-RX-API-DMAC10.html)
JP (1) JP5074184B2 (cg-RX-API-DMAC10.html)
KR (1) KR20070027649A (cg-RX-API-DMAC10.html)
CN (1) CN101094666B (cg-RX-API-DMAC10.html)
AT (1) ATE441406T1 (cg-RX-API-DMAC10.html)
DE (1) DE602005016405D1 (cg-RX-API-DMAC10.html)
ES (1) ES2331083T3 (cg-RX-API-DMAC10.html)
WO (1) WO2006002735A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084687A1 (en) * 2005-02-11 2006-08-17 Dsm Ip Assets B.V. Use of zeaxanthin for the treatment of diseases of the peripheral retina
AT503329A1 (de) 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
US5827652A (en) * 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
FR2749758B1 (fr) * 1996-06-12 1998-08-07 Oenobiol Sa Lab Composition a activite bronzante et photoprotectrice et ses applications esthetiques
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6712466B2 (en) * 2001-10-25 2004-03-30 Ophthonix, Inc. Eyeglass manufacturing method using variable index layer
WO2003063848A1 (en) * 2002-01-30 2003-08-07 Dsm Ip Assets B.V. Lutein/zeaxanthin for glare protection
CN1481804A (zh) * 2002-12-17 2004-03-17 无锡杰西医药科技有限公司 防治白内障、黄斑变性等眼病的配方及其使用方法

Also Published As

Publication number Publication date
WO2006002735A1 (en) 2006-01-12
JP5074184B2 (ja) 2012-11-14
KR20070027649A (ko) 2007-03-09
EP1761254A1 (en) 2007-03-14
EP1761254B1 (en) 2009-09-02
ES2331083T3 (es) 2009-12-21
ATE441406T1 (de) 2009-09-15
JP2008505137A (ja) 2008-02-21
CN101094666A (zh) 2007-12-26
CN101094666B (zh) 2010-09-29
US20110172313A1 (en) 2011-07-14
US20080045605A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
ES2955713T3 (es) Agente de mejora de la función visual, y método para mejorar la función visual
EP4442241A3 (en) Retinol replacement in skin treatment
Pinto et al. N-Acetylcysteine treatment reduces TNF-α levels and myonecrosis in diaphragm muscle of mdx mice
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
EP4371615A3 (en) Treatment of amd using aav sflt-1
CR9994A (es) Vacuna terapéutica
PL1639013T3 (pl) Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu
NO20092633L (no) Ernaeringstilskuddsammensetning for behandling av okulare sykdommer
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
DK2111125T3 (da) Flydende formuleringer indeholdende carotinoider
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
MX2007001943A (es) Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
Musa et al. Nutritional factors: benefits in glaucoma and ophthalmologic pathologies
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
AR079696A1 (es) Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular
GB201310235D0 (en) Nutraceutical and pharmaceutical composition
UY34040A (es) Composiciones para disimular sabores y sus formas comestibles
WO2020142607A3 (en) Uv screening and antioxidant composition and use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition